Iteos Therapeutics Inc

NASDAQ ITOS

Data sourced from iex and EODHD
Download Data

Iteos Therapeutics Inc Income Statement 2018 - 2023

This table shows the Income Statement for Iteos Therapeutics Inc going from 2018 until 2023. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Revenue
M 13 268 345 0 0 0
Cost of Revenue
M 1 1 1 1 - -
Gross Profit
M 12 267 344 -1 - -
Operating Expenses
M 163 140 99 45 - -
Selling, General, and Administrative Expenses (SG&A)
M 50 44 41 15 9 4
Research and Development (R&D) Expenses
M 113 97 59 30 19 17
Other Operating Expenses
M -1 -1 -1 -1 - -
Costs and Expenses
M 157 137 89 39 - -
Operating Income
M -151 126 245 -45 -28 -22
Interest Expense
M - 19 1 1 0 0
Non-operating Income/Expense
M 4 22 12 7 6 0
EBT
M -109 149 256 -38 -22 -18
Income Tax Provision
M 4 52 42 0 0 0
Income after Tax
M -113 97 215 -38 -22 -18
Non-Controlling Interest
M - 0 0 5 4 2
Net Income
M - 97 215 -43 -27 -20
Shares (Basic, Weighted)
M - - - - - -
Shares (Diluted, Weighted)
R 35,763,520.00 37,766,507.00 37,774,790.00 35,044,758.00 9,912,494.00 7,510,702.00
EBITDA
M -144 130 256 -39 -22 -17
Depreciation and Amortization
M 1 4 11 6 6 1
EBIT
M -145 126 245 -45 -28 -18
Income from Discontinued Operations
M - - - - - -
Tax Rate (Effective)
% -3.31 35.02 16.35 0.15 -0.53 -0.06
Earnings Per Share (EPS), Basic
M - - - - - -
Earnings Per Share (EPS), Diluted
M - 0 0 0 0 0
Gross Profit Margin
% 92.87 99.70 99.82 - - -
Operating Income Margin
% -1,199.69 47.20 71.03 - - -
Net Income Margin
% - 36.11 62.22 - - -
EBITDA Ratio
% -1,143.22 48.72 74.16 - - -
EBIT Ratio
% -1,150.35 47.20 71.03 - - -
EBT Ratio
% -865.66 55.58 74.39 - - -

StockViz Staff

September 19, 2024

Any question? Send us an email